| Literature DB >> 24758161 |
Alicia M Maceira, Carmen Ripoll, Juan Cosin-Sales, Begoña Igual, Mirella Gavilan, Jose Salazar, Vicente Belloch, Dudley J Pennell1.
Abstract
BACKGROUND: Cocaine is an addictive, sympathomimetic drug with potentially lethal effects. The prevalence and features of cocaine cardiotoxicity are not well known. We aimed to assess these effects using a comprehensive cardiovascular magnetic resonance (CMR) protocol in a large group of asymptomatic cocaine users.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24758161 PMCID: PMC4026110 DOI: 10.1186/1532-429X-16-26
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Exclusion criteria
| • Diabetes mellitus, defined as plasma glucose >126 mg/dL or use of antidiabetic drugs | |
| • Severe chronic renal insufficiency (GFR < 30 mL/min/1.73 m2 calculated with the MDRD equation) | |
| • AIDS diagnosis, conditions with short life-expectancy | |
| • Consumption of design drugs within the last 5 years* | |
| • Allergy to iodine or gadolinium based contrast agents | |
| • Claustrophobia | |
| • Metallic implants (eg pacemakers, defibrilators) | |
| • Acute psychotic attack |
*Design drugs investigated were METH (methamphetamine, also called speed, crystal meth), MDA (3,4- methylenedioxyamphetamine, also known as love drug), MDMA (3,4-methylenedioxy-N-methylamphetamine, also known as ecstasy) and MDEA / MDE (3,4- methylenedioxy –N-ethylamphetamine, also called Eve).
Figure 1Patient recruitment and final participation in the study.
Data on cocaine and alcohol use
| Cocaine | Age at the time of first use, yrs | 22.7 ± 6.7 |
| | Time between last use and CMR, days | 53 ± 40 |
| | Frequency of use in the past (number of uses) | 3.2 ± 1.8 |
| | Frequency of use in the past 3 months (uses per month) | 3.8 ± 1.6 |
| | Maximum frequency of use in lifetime (uses per month) | 7.5 ± 1.5 |
| | Amount of consumption in the past month (g) | 3.8 ± 1.6 |
| | Years of regular cocaine use (yrs) | 13.9 ± 9 |
| | Route of administration | |
| | Nasal insufflation | 81% |
| | Smoked | 16% |
| | Intravenous | 3% |
| Alcohol | Subjects with alcohol abuse or dependence, n (%) | 49 (51%) |
| | Age at the time of first use, yrs | 16 ± 4 |
| | Time between last use and CMR (days) | 120 ± 237 |
| | Frequency of use in the past month (number of uses) | 2.7 ± 2.3 |
| | Frequency of use in the past 3 months (uses per month) | 2.8 ± 2.3 |
| | Amount of use in the past month (gr) | 120 ± 170 |
| Years of alcohol use | 20 ± 7 yrs |
Biological data and cardiovascular risk factors
| Males/females | 81/13 |
| Age (yrs) | 36.6 ± 7 |
| Heart rate (bpm) | 71 ± 12 |
| SBP (mmHg) | 127 ± 10 |
| DBP (mmHg) | 82 ± 11 |
| Weight (Kg) | 77 ± 16 |
| Height (cm) | 173 ± 7 |
| Body mass index (Kg/m2) | 25.8 ± 4.5 |
| Subjects with overweight, n (%) | 27 (28.7%) |
| Subjects with obesity, n (%) | 8 (8.5%) |
| Smoking habitus | |
| Currently smoking, n (%) | 71 (75%) |
| Ex–smoker, n (%) | 5 (5.3%) |
| Years of smoking habitus | 13.5 ± 9.1 |
| Cigarettes per day | 13 ± 7 |
| Dyslipidaemia, n (%) | 10 (10.6%) |
| Years of known dyslipidaemia | 1.9 ± 2.0 |
| Hypertension, n (%) | 4 (4.2%) |
| Years of known hypertension | 3.6 ± 6.4 |
| Family history of CAD, n (%) | 6 (6.3%) |
SBP systolic blood pressure, DBP diastolic blood pressure.
Laboratory findings
| usCRP (mg/L)* | 1.8 (0.2 , 32) |
| subjects increased with usCRP (n, %) | 18, 19 |
| Glucose (mg/dL) | 79 ± 18 |
| Total cholesterol (mg/dL) | 250 ± 42 |
| LDL cholesterol (mg/dL) | 127 ± 33 |
| Triglycerides (mg/dL) | 244 ± 140 |
| Fibrinogen (mg/dL) | 475 ± 45 |
| Gammaglutamiltranspeptidase (IU/L) | 79 ± 32 |
| Fosfatase alkaline (IU/L) | 159 ± 29 |
*usCRP is presented as median (minimum, maximum).
Per-group analysis of CMR derived parameters
| LVEDVi (mL/m2) | 72 ± 15 | 76 ± 9 | NS |
| LVESVi (mL/m2) | 30 ± 8 | 26 ± 5 | < 0.01 |
| LVSVi (mL/m2) | 42 ± 9 | 51 ± 6 | < 0.01 |
| LVEF (%) | 59 ± 5 | 68 ± 4 | < 0.01 |
| LVMi (g/m2) | 76 ± 15 | 69 ± 4 | 0.015 |
| RWM (g/mL) | 1.07 ± 0.22 | 0.87 ± 0.12 | < 0.01 |
| RVEDVi (mL/m2) | 74 ± 16 | 79 ± 11 | NS |
| RVESVi (mL/m2) | 36 ± 9 | 28 ± 4 | < 0.01 |
| RVSV (mL/m2) | 42 ± 9 | 51 ± 7 | < 0.001 |
| RVEF (%) | 56 ± 5 | 65 ± 5 | < 0.001 |
| LA AP diameter (cm) | 31.2 ± 5.1 | 30.8 ± 4.8 | NS |
| LA area (cm2) | 23.5 ± 4.0 | 24.7 ± 4.0 | NS |
LV left ventricle; RV right ventricle; EDVi end-diastolic volume index, ESVi left ventricular end-systolic volume index, SVi stroke volume index, EF left ventricular ejection fraction, LVMi left ventricular mass index, RWM relative wall mass, LA: left atrium, AP anteroposterior.
Figure 2Per-patient analysis of LV and RV parameters in cocaine abusers (black dots) compared to reference values (mean: black line, red: upper limit of normal, blue: lower limit of normal) showing that a substantial number of asymptomatic cocaine abusers show mild biventricular dilatation and systolic dysfunction, as well as LV hypertrophy. LV left ventricle; RV right ventricle; EDVi end-diastolic volume index; ESVi, end-diastolic volume index; EF ventricular ejection fraction; LVMi, left ventricular mass index.
Figure 3Regional wall motion abnormalities (arrows) were found in 4 subjects. A) and C) mild anteroapical hypokinesia; B) Apicolateral hypokinesia; D) distal septum hypokinesia.
Figure 4Late gadolinium enhancement (LGE) in 4 cocaine abusers (arrows). A) focal subepicardial LGE at the distal mid-lateral wall. B) several intramyocardial foci of LGE in the inferolateral and lateral wall. C) focal LGE in the mid inferior ventricular junction. D) limited subendocardial LGE in the basal inferior wall.